Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Rhea-AI Summary

Roivant (ROIV) and Pulmovant will present topline Phase 2 PHocus results for mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease at the European Respiratory Society International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026.

The talk will be given by Marc Humbert, MD, PhD. Roivant will also host an investor call and webcast at 8:00 a.m. ET the same day, with access details and an archived webcast available in the Investors “Events & Presentations” section of its website.

Market Context

Recent ROIV insider activity recorded 1,400,000 shares sold and no purchases. That platform signal a...

Analysis

Recent ROIV insider activity recorded 1,400,000 shares sold and no purchases. That platform signal adds cautionary context to the scheduled clinical readout; the active shelf and eventual topline details were key items to monitor.

Key Figures

Trial phase: Phase 2 Presentation date: September 8, 2026 Presentation time: 12:15 CEST +1 more

4 metrics

Trial phase Phase 2 PHocus study of mosliciguat

Presentation date September 8, 2026 ERS International Congress 2026

Presentation time 12:15 CEST ERS Congress presentation

Investor call time 8:00 a.m. ET September 8, 2026

Historical Context

4 past events · Latest: Aug 27 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 27	FDA approval	Positive	+2.2%	LISRAYA received FDA approval for adults with dermatomyositis.
Aug 26	Clinical data	Positive	+0.8%	Phase 3 VALOR skin-specific outcomes showed improved response versus placebo.
Aug 06	Clinical enrollment	Positive	+1.5%	BEACON+ enrolled first patients in a Phase 3 cutaneous sarcoidosis study.
Aug 06	Earnings report	Negative	+1.5%	Quarterly results included a $290.6 million net loss and $1.4 million revenue.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ROIV showed positive 24-hour reactions to three recent clinical or regulatory updates, while the August 6 earnings event diverged amid reported losses.

Key Terms

pulmonary hypertension, interstitial lung disease, ph-ild, phase 2

4 terms

pulmonary hypertension medical

"mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease"

Pulmonary hypertension is a condition where the blood vessels in the lungs become narrowed or stiff, forcing the right side of the heart to work much harder to push blood through—imagine a pump trying to push water through narrower pipes. For investors, it matters because the condition drives demand for diagnostic tests, ongoing treatments, and new drugs; changes in clinical trial results, approvals, or treatment guidelines can meaningfully affect the commercial prospects and costs for companies focused on this disease.

interstitial lung disease medical

"pulmonary hypertension associated with interstitial lung disease (PH-ILD)"

A group of lung conditions that cause inflammation and scarring of the thin tissue between the air sacs, which makes it harder for oxygen to pass into the blood; imagine the lungs’ fine filters becoming stiff and less effective. Investors care because reports of interstitial lung disease can affect a drug’s safety profile, trigger regulatory warnings or label changes, and shift demand for treatments or create liability risks that influence a company’s valuation.

ph-ild medical

"interstitial lung disease (PH-ILD) will be presented"

PH-ILD stands for pulmonary hypertension associated with interstitial lung disease, a condition where stiff or scarred lung tissue makes it harder to move oxygen into the blood and causes dangerously high blood pressure in the lung arteries. Investors care because it signals a serious, progressive illness with limited treatment options, shaping demand for therapies, clinical trial design, regulatory review and long-term revenue potential in respiratory and cardiovascular drug markets.

phase 2 technical

"results from the Phase 2 PHocus study of mosliciguat"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026.

To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at www.investor.roivant.com/news-events/events.  The archived webcast will be available on Roivant’s website after the conference call.

About Roivant
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.

Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.

Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. In addition, any statements that refer to projections, forecasts or other characterizations of future events, results or circumstances, including any underlying assumptions, are forward-looking statements. Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:
Investors
Keyur Parekh
keyur.parekh@roivant.com 

Media
Stephanie Lee
stephanie.lee@roivant.com 

FAQ

When will Roivant (ROIV) present Phase 2 PHocus topline results for mosliciguat in PH-ILD?

Roivant and Pulmovant will present topline results from the Phase 2 PHocus study of mosliciguat in pulmonary hypertension associated with interstitial lung disease at the European Respiratory Society International Congress 2026 on Tuesday, September 8, 2026, at 12:15 CEST (6:15 a.m. ET).

Who is presenting the PHocus Phase 2 mosliciguat data for Roivant (ROIV) at ERS 2026?

The Phase 2 PHocus results for mosliciguat in PH-ILD will be presented by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.

When is Roivant (ROIV) hosting the investor call for the Phase 2 PHocus mosliciguat results?

Roivant will host an investor call and webcast on Tuesday, September 8, 2026, at 8:00 a.m. ET. The company will discuss the topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease.

How can investors access Roivant’s investor call and webcast on the Phase 2 PHocus mosliciguat study (ROIV)?

To access the investor conference call by phone, participants should register online using the provided registration link. Presentation and webcast details will also be available under “Events & Presentations” in the Investors section of Roivant’s website.

Will a replay or archived webcast of Roivant’s Phase 2 PHocus investor call be available?

Yes. An archived webcast of Roivant’s investor call and webcast related to the Phase 2 PHocus study of mosliciguat will be available on the company’s website after the conference call, in the Investors “Events & Presentations” section.